PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Last updated: March 6, 2025
Sponsor: University of California, San Francisco
Overall Status: Active - Recruiting

Phase

1

Condition

Wolman Disease

Hunter Syndrome (Mps Ii)

Pompe Disease

Treatment

Aldurazyme (laronidase)

Clinical Study ID

NCT04532047
20-31520
  • Ages 18-50
  • Female

Study Summary

For detailed information, please view our study website: https://pearltrial.ucsf.edu/

The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Live male or female fetuses at 18 0/7 weeks to 34 6/7 weeks gestation

  • Diagnosis of one of the 8 included LSDs in utero by genetic or enzymatic analysesperformed on amniotic fluid, fetal blood, placental tissue, or other samples throughchorionic villus sampling (CVS), amniocentesis, cordocentesis, cell free fetal DNA,or other procedures. In the event that parents are identified as genetic carriersfor a LSD, diagnostic testing for the fetus would be performed to confirm thediagnosis

  • Pregnant women age 18 years to 50 years, carrying a live male or female fetus at 18 0/7 weeks to 34 6/7 weeks gestation

  • Identified through the above listed means to be carrying a fetus with an LSD.

  • Ability to give written informed consent and comply with the requirements of thestudy.

Exclusion

Exclusion Criteria:

  • Fetuses with a concurrent severe structural anomaly

  • Fetuses with an additional pathogenic genetic variant not related to the underlyingLSD that contribute a significant risk of morbidity or mortality.

Hydrops fetalis will not be an exclusion criterion because ERT has the possibility of significant benefit in this situation.

  • Women with one or more significant comorbidities that would preclude fetalintervention including, but not limited to:

  1. inability to complete the procedure secondary to maternal body habitus orplacental location

  2. significant cardiopulmonary disease

  3. mirror syndrome

  4. end organ failure

  5. altered mental status

  6. placental abruption

  7. active preterm labor

  8. preterm premature rupture of membranes.

  • Mother will require therapeutic dosing of anticoagulation within 24 hours prior toor following the intervention.

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: Aldurazyme (laronidase)
Phase: 1
Study Start date:
July 01, 2021
Estimated Completion Date:
July 31, 2032

Study Description

Because fetuses with these LSDs are at increased risk of serious perinatal morbidity and mortality, particularly in the setting of Non-Immune Hydrops Fetalis (NIHF), the administration of the approved enzyme therapy in utero has the potential to significantly improve outcomes for affected fetuses. The perinatal death rate associated with NIHF ranges from 30 to 75%, so development of an in utero approach to treatment could be of significant benefit. The in utero period has been shown to be a time of relative fetal tolerance to immune stimuli, and this tolerance may lead to improved response to ERT in situations where postnatal initiation instead leads to antibody development and impaired response to treatment. It is also probable that in some cases, initiation of ERT in utero leads to improved neurodevelopmental outcomes if the replaced enzyme impacts the neurologic system during critical periods of development.

This is a phase 1 clinical trial to determine the safety and feasibility of fetal enzyme replacement therapy in fetuses with LSD

Connect with a study center

  • University of California

    San Francisco, California 94158
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.